Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- NHANES Analyses Shed Light on Expanded Statin Eligibility, Treatment Gaps Under 2026 ACC/AHA Dyslipidemia GuidelineThree studies using National Health and Nutrition Examination Survey (NHANES) data published July 20 in JAMA provide new insights into LDL-C treatment goals under the 2026 ACC/AHA Guideline on the Management of Dyslipidemia.
- Eagle’s Eye View: ACC Updated Expert Consensus Decision Pathway on HFpEFIn this week’s View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis.
- Indexing Ascending Aortic Dimensions to Height vs. Absolute Diameter to Identify High-Risk PatientsIndexing ascending aortopathy (AA) to height better identifies patients, especially women, who could benefit from earlier surgery rather than absolute diameters, according to a recent study published in JACC: Advances.
- Higher TAVR Volume Associated With Lower Complications, Not Lower Failure to Rescue Rates | NCDR StudyHigher annualized TAVR volume is associated with lower complication rates but not with lower failure to rescue (FTR) rates, according to a recent study published in JACC: Cardiovascular Interventions.
- OPTIMA-AF: 1-Month vs. 12-Month Dual Antithrombotic Therapy Post PCIOnly one month of dual antithrombotic therapy followed by direct oral anticoagulant (DOAC) monotherapy proved to be noninferior in terms of efficacy and superior in terms of bleeding outcomes to the standard 12-month dual antithrombotic therapy post PCI among patients with atrial fibrillation (AFib), according to results of the OPTIMA-AF trial published July 15 in […]



